Multiple sclerosis in the Arabian Gulf countries: A consensus statement

Journal of Neurology

Volumn 260, Issue 12, 2013, Pages 2959-2963

  Bohlega, Saeed ^a   Inshasi, Jihad ^b   Al Tahan, Abdel Rahman ^c   Madani, Abu Bakr ^b   Qahtani, Hussien ^d   Rieckmann, Peter ^e  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b RASHID HOSPITAL   (United Arab Emirates)

^c KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^d King Khaled National Guard   (Saudi Arabia)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Arabian Gulf; Diagnosis; Guidelines; Multiple sclerosis; Treatment

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; STEROID; VITAMIN D;

CEREBROSPINAL FLUID ANALYSIS; CONSENSUS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DUBAI; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

HUMANS; MIDDLE EAST; MULTIPLE SCLEROSIS;

EID: 84890799004     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6876-4     Document Type: Review

References (20)

1. Alshubaili AF, Alramzy K, Ayyad YM, Gerish Y (2005) Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol 53:125-131
2. Yaqub BA, Daif AK (1988) Multiple sclerosis in Saudi Arabia. Neurology 38(4):621-623
3. Daif AK, Al-Rajeh S, Awada A, Al Bunyan M, Oqunniyi A, Abdul Jabar M, Al Tahan AR (1998) Pattern of presentation of multiple sclerosis in Saudi Arabia: analysis based on clinical and paraclinical features. Eur Neurol 39(3):182-186
4. Inshasi J, Thakre M (2011) Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci 121(7):393-398
5. Naeem Z (2010) Vitamin D deficiency - an ignored epidemic. Int J Health Sci 4:5-6
6. Denic S, Bener A (2001) Consanguinity decreases risk of breast cancer-cervical cancer unaffected. Br J Cancer 85(11):1675-1679
7. Al Jumah M, Kojan S, Al Khathaami A, Al Abdulkaream I, Al Blawi M, Jawhary A (2011) Familial multiple sclerosis: does consanguinity have a role? Mult Scler 17(4):487-489
8. Schwid SR, Bever CT (2001) The cost of delaying treatment in multiple sclerosis. Neurology 56:1620
9. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4(5):281-288
10. Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898-904
11. Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576-1582
12. Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389-397
13. Zwibel H (2011) Long-term experience of glatiramer acetate (Copaxone) in the treatment of clinically isolated syndrome and relapsing-remitting multiple sclerosis. US Neurol 7(2):126-131
14. Ziemssen T, Schrempf W (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 79:537-570
15. Gonsette RE (2007) Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 8(8):1103-1116
16. Murray TJ (2006) The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? Expert Opin Drug Saf 5(2):265-274
17. Hartung HP (2005) Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 252(Suppl 3):iii44-iii50
18. Rio et al (2011) Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 24 (3) June 2011
19. Rio J et al (2006) Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344-352
20. Myhr KM (2009) Vitamin D treatment in multiple sclerosis. J Neurol Sci 286(1-2):104-108